Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis

Hibi, Toshifumi; Kamae, Isao; Pinton, Philippe; Ursos, Lyann; Iwakiri, Ryuichi; Hather, Greg; Patel, Haridarshan

doi:10.5217/ir.2019.09146

Cited by 18 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As there have been few reports about the effectiveness and safety of golimumab in Asian patients, we followed 133 patients with moderate-to-severe UC of about 5 years in 43 teaching hospitals in South Korea to evaluate them in real world. 30 Our study demonstrated the effectiveness of golimumab in Korean patients with moderate-to-severe UC that was consistent with previous studies. 19,25,31,32 After induction dosage regimen of golimumab, more than half of the patients (56%) achieved clinical response at week 6, and more than two-thirds of the patients (67.9%) achieved clinical response at week 22.…”

Section: Discussionsupporting

confidence: 92%

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study

Park

Kim

et al. 2021

Gut and Liver

View full text Add to dashboard Cite

Background/Aims: Golimumab has been used for patients with ulcerative colitis (UC) since 2013. However, there is limited data on the effectiveness and safety of the real-world use of golimumab in Asian patients. Methods:This was a multicenter, prospective, observational study. We enrolled patients with moderate-to-severe UC who were administered subcutaneous golimumab at 46 medical centers between May 2014 and November 2019. The primary outcome was the effectiveness and safety of golimumab at week 22. Clinical outcomes and adverse events were assessed according to partial Mayo score at weeks 0, 2, 6, 14, and 22.Results: A total of 130 patients were included (mean age: 45.7±16.0 years). The clinical response/ remission rates at weeks 2, 6, 14, and 22 were 40.4%/22.9%, 56.0%/35.8%, 70.6%/49.5%, and 67.9%/48.6%, respectively. Based on full Mayo score at week 14, clinical response and remission rates were 84.2% and 39.5%, respectively. Mucosal healing rate was 65.8%. In multivariate analysis with logistic regression, longer disease duration was significantly associated with a higher clinical response rate (adjusted odds ratio [aOR], 1.136; 95% confidence interval [CI], 1.006 to 1.282; p=0.040 at week 6; aOR, 1.256; 95% CI, 1.049 to 1.503; p=0.013 at week 22). A higher baseline Mayo endoscopic subscore was significantly associated with a lower clinical response rate at week 6 (aOR, 0.248; 95% CI, 0.089 to 0.692; p=0.008). The incidence of adverse drug reactions was 4.6% (6/130, nine events). No serious unexpected adverse drug reactions or deaths were reported. Conclusions:Golimumab was effective and safe as an induction and maintenance treatment for Korean patients with moderate-to-severe UC.

show abstract

Section: Discussionsupporting

confidence: 92%

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study

Park

Kim

et al. 2021

Gut and Liver

View full text Add to dashboard Cite

show abstract

“…However, anti-TNF therapy increases the risk of infection [ 12 , 13 ]. Tuberculosis (TB) is one infection associated with anti-TNF therapy, which is thought to inhibit the formation of granuloma and thus prevent the suppression of TB activation [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

Lee

Hong

et al. 2021

BMC Gastroenterol

View full text Add to dashboard Cite

Background Anti-tumor necrosis factor (TNF) treatment for inflammatory bowel disease (IBD) increases the risk of tuberculosis (TB) infection. In the present study, we analyzed the clinical characteristics and risks of TB in Korean patients with IBD who received anti-TNF treatment. Methods The study included patients with IBD who were treated using anti-TNF agents between January 2001 and June 2018 at the Asan Medical Center. Overall, 1434 patients with ulcerative colitis or Crohn’s disease were enrolled. We calculated the incidence of active TB infection after anti-TNF treatment and compared the clinical characteristics of the TB group with those of the non-TB group. Results Twenty-one patients (1.46%) developed active TB infection, and the incidence rate of active TB was 366.73 per 100,000 person-years. In total, 198 patients (14.9%) were positive for latent tuberculosis infection (LTBI), of whom only eight (4%) did not complete LTBI treatment. The age at which the anti-TNF therapy was started was significantly higher in the TB group than in the non-TB group (HR 1.041, 95% CI 1.014–1.069, p = 0.002), and as age increased, so did the incidence rate of active TB infection (linearity p < 0.001). There was no significant difference in the incidence rate of LTBI between the TB and non-TB groups (HR 0.896, 95% CI 0.262–3.066, p = 0.862). Conclusions In patients with IBD, the incidence rate of TB increased with age at anti-TNF therapy initiation. Active treatment of LTBI may lower the incidence of TB in patients with IBD who are to undergo anti-TNF therapy.

show abstract

“…17,26 Our study has highlighted the difference in biomarker dynamics between patients who required and avoided colectomy and demonstrated the potential utility of CAR and CLR early in the treatment course (day 3 post salvage) in predicting infliximab failure. With the expansion of efficacious treatments such as newer biologic therapies and small molecule inhibitors, [27][28][29][30] the ability to predict disease trajectory in ASUC should inform treatment choice-for example, a patient who is likely to require longer term colectomy despite infliximab salvage may warrant more proactive optimization of maintenance therapy with a biologic agent (a top-down approach), while patients with a lower risk of colectomy may only require conventional therapy. [31][32][33] Although the ability to continue biologic therapy in all patients may appear attractive, a careful risk-benefit assessment should be made given such a strategy introduces an additional risk of infections and may not be cost-effective.…”

Section: Discussionmentioning

confidence: 99%

Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy

et al. 2022

View full text Add to dashboard Cite

cerative colitis (ASUC) is a severe exacerbation of UC that warrants intravenous corticosteroids and may require emergency colectomy. 3 Corticosteroid failure necessitates salvage therapy with infliximab or ciclosporin which have demonstrated good short term efficacy. [4][5][6][7] However longer term prognosis after medical salvage remains guarded, where up to 50% of patients still proceed to colectomy in the absence of maintenance biologic therapy. [8][9][10] Conversely, a proportion of patients may have an initial period of significant symptoms, but develop only mild symptoms or even remission in the subsequent 10 years of

show abstract

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis

Cited by 18 publications

References 21 publications

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study

Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy

Contact Info

Product

Resources

About